BioCryst begins Phase 1 BCX4161 study for hereditary angioedema treatment
Phase 1 trial will assess the safety, pharmacokinetic and pharmacodynamic profile of BCX4161, a novel selective inhibitor of plasma kallikrein, in healthy volunteers. The study that is being